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Pseudomonas aeruginosa is a highly versatile opportunistic pathogen and its ability to
produce bioﬁlms is a direct impediment to the healing of wounds and recovery from
infection. Interest in anti-microbial peptides (AMPs) has grown due to their potential ther-
apeutic applications and their possible use against antibiotic resistant bacteria. LL-37 is the
only cathelicidin expressed by humans. In this study, we tested LL-37 and the effect of a
protease-resistant LL-37 peptidemimetic, the peptide enantiomer D-LL-37, for anti-microbial
and anti-bioﬁlm activity against P. aeruginosa. Both forms of the peptide were equally
effective as AMPs with similar killing kinetics. Circular dichroism spectra were obtained
to demonstrate the chirality of D- and L-LL-37, and the trypsin resistance of D-LL-37 was
conﬁrmed.The helical cathelicidin from the cobra Naja atra (NA-CATH), and synthetic pep-
tide variations (ATRA-1, ATRA-2, NA-CATH:ATRA1-ATRA1) were also tested. Although the
cobra cathelicidin and related peptides had strong anti-microbial activity, those tested did
not inhibit Pseudomonas bioﬁlm formation, neither did control peptides. Both D- and L-LL-
37 inhibited the attachment of Pseudomonas to a 96-well plate and decreased the amount
of pre-formed (established) bioﬁlm. D-LL-37 is able to promote Pseudomonas motility and
decrease bioﬁlm formation by altering the rate of twitching as well as by downregulating
the expression of the bioﬁlm-related genes, rhlA and rhlB, similar to L-LL-37. Both L- and
D-LL-37 protected Galleria mellonella in vivo against Pseudomonas infection, while NA-
CATH:ATRA1-ATRA1 peptide did not. This study demonstrates the ability and equivalence
of D-LL-37 compared to L-LL-37 to promote bacterial twitching motility and inhibit bioﬁlm
formation, and protect against in vivo infection, and suggests that this peptide could be a
critical advancement in the development of new treatments for P. aeruginosa infection.
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INTRODUCTION
Pseudomonas aeruginosa, a Gram-negative bacterium, is a major
cause of hospital-associated infections, causing ∼10% of nosoco-
mial infections (Hancock and Speert, 2000),with a sepsismortality
rate of nearly 50% (Bone, 1993). This opportunistic pathogen can
cause pneumonia, catheter-associated and urinary tract infections,
and sepsis in wounded patients and those who are immuno-
compromised (Van Delden and Iglewski, 1998). P. aeruginosa is
the most clinically relevant pulmonary pathogen in patients with
cystic ﬁbrosis, causing chronic infections, and is the most com-
mon cause of fatal lung disease (Richards et al., 1999), as well as
the most frequently recorded cause of hospital-acquired pneumo-
nia, with an increasing number of these cases involving antibiotic
resistant strains (Rello et al., 1993; Heyland et al., 1999).
In order for the opportunistic pathogen P. aeruginosa to infect
a host, it requires a break in the innate immunological defenses.
Abbreviations: AMP, anti-microbial peptide; CAMP, cationic anti-microbial pep-
tide; CFU, colony forming unit; EC50, half-maximal effective concentration; MIC,
minimum inhibitory concentration; TFE, triﬂuoroethanol.
Once established within the host, the ability of P. aeruginosa to
form bioﬁlm is a signature characteristic for it to become a chronic
infection (Hoiby et al., 2001; Singh et al., 2002). This property
has made Pseudomonas a model organism in the study of bioﬁlm
formation. Bioﬁlms, non-motile communities enveloped in an
exopolysaccaride and extracellular protein secretion that enhances
survival, are often physically resistant to anti-microbial agents and
host immune responses (Stewart et al., 2001; Donlan and Coster-
ton, 2002; Drenkard and Ausubel, 2002). It has been shown that
bioﬁlm formation can be a pathogen’s defensive reaction to the
presence of antibiotics. Speciﬁcally, subinhibitory concentrations
of antibiotics can initiate the production of the exopolysaccha-
ride matrix by P. aeruginosa, and stimulate increases in bioﬁlm
volume (Rachid et al., 2000; Bagge et al., 2004). The clinical use
of current antibiotics at concentrations effective for eliminating
bioﬁlms would result in signiﬁcant systemic side effects, limit-
ing their utility in such cases (Whatley et al., 2006). In addition
to P. aeruginosa infections in burn victims (Ressner et al., 2008),
examples of bioﬁlm-associated infections include: pneumonia and
cystic ﬁbrosis (Hoiby et al., 2001; Singh et al., 2002), chronic
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wounds such as diabetic foot ulcers, sinus and ear infections, and
endocarditis (Costerton et al., 1999; Prince, 2002; Dieter, 2004;
Kaneko et al., 2007).
Anti-microbial peptides (AMPs) are critical components of
innate immunity in humans, contributing to our ﬁrst line of
defense against infection (Zasloff, 2002). The cathelicidin fam-
ily of AMPs range from 12 to 80 amino acid residues in length,
and are identiﬁed based on a conserved N-terminal domain, the
cathelin domain, present in the inactive precursor peptide (cleaved
from the active peptide) within the granules of natural killer T
cells, in the mucosal epithelia of the lungs, and other sites (Ganz
and Weiss, 1997). The sequence diversity of cathelicidins trans-
lates into the peptides demonstrating structural diversity, which
can be grouped into sub-classes based on shared structural fea-
tures.Alpha-helical cathelicidins,which adopt amphipathic helical
conformations when interacting with membranes, are the largest
of the cathelicidin structural classes. Our knowledge of their
structural and functional properties is largely based on observa-
tions from the single, highly studied human cathelicidin, LL-37
(Gennaro et al., 1998).
The single human cathelicidin LL-37 is derived from the
C-terminus of the human CAP-18 protein. It is a 37 residue
cationic peptide which forms an alpha-helix when in contact
with bacterial membranes. This peptide has broad-spectrum anti-
microbial activity against Gram-negative and Gram-positive bac-
teria, including against P. aeruginosa (EC50 of 2.8± 1.3μg/ml;
Bals et al., 1998; Turner et al., 1998; Travis et al., 2000; Saiman
et al., 2001; Bucki et al., 2004; Gordon et al., 2005). However,
multi-drug resistant P. aeruginosa strains exhibit reduced sensi-
tivity to several AMPs (Ouhara et al., 2008), demonstrating the
need to identify more effective AMPs. In order to develop addi-
tional AMPs we decided to test the impact of peptide chirality on
the anti-microbial effectiveness of LL-37. We synthesized a D-LL-
37 peptide, in which each amino acid residue of the naturally
occurring L-isomer had been replaced with the corresponding
D-amino acid reside. This peptide exhibits immunostimulatory
activity more potent than that of LL-37 (induction of IL-8 in
keratinocytes and promoting ﬁbroblast proliferation; Braff et al.,
2005a), which suggests the interaction between the cathelicidin
peptide and the host cellular membrane or intracellular targets
may be complex, perhaps involving receptors that exhibit chiral
discrimination and recognition.
There are only a few studies that show peptides with anti-
bioﬁlm activity against P. aeruginosa. We and others have demon-
strated the anti-bioﬁlm activity of synthetic peptide mimics
of AMPs against Staphylococcus aureus, and other pathogens
(Beckloff et al., 2007; Pollard et al., 2009; Amer et al., 2010; Dean
et al., 2011; Leszczynska et al., 2011). In vivo, a 24-residue LL-
37-derived AMP was shown to degrade established P. aeruginosa
bioﬁlm in an animals’ nasopharynx, however the signiﬁcant effect
required 2.5mg/ml of peptide, a high concentration for ther-
apeutic use (Chennupati et al., 2009). Overhage et al. (2008)
demonstrated that 4μg/ml LL-37 was able to reduce pre-formed
Pseudomonas bioﬁlm formation in vitro, and that LL-37 treatment
affected gene expression of many bioﬁlm-related genes in P. aerug-
inosa PAO1, including the signiﬁcant downregulation of rhlA and
rhlB expression.
A recently identiﬁed helical cathelicidin from the elapid snake
Bungarus fasciatus (BF) was found to be antimicrobial against
P. aeruginosa (MIC of 1.2μg/ml; Wang et al., 2008). A related
cathelicidin peptide that has shown to be a potent anti-microbial
against many bacteria was discovered in the elapid snake Naja
atra (NA), the Chinese Cobra, but has not been previously tested
against P. aeruginosa. We previously observed that the 39 residue
amino acid sequence of the NA cathelicidin (NA-CATH) con-
tains an imperfect, repeated 11 residue motif (ATRA), larger than
what was ﬁrst described by Zhao et al. (Zhao et al., 2008; Amer
et al., 2010; de Latour et al., 2010). We previously designed and
synthesized a peptide called NA-CATH:ATRA1-ATRA1 to explore
the signiﬁcance of the conserved residues within the ATRA motif
for anti-microbial and anti-bioﬁlm activity against Staphylococ-
cus aureus (Dean et al., 2011). In this study, we test the ATRA
family of peptides against Pseudomonas. In addition, we have syn-
thesized the D-form of LL-37 as a peptide mimetic to address the
protease-sensitivity concern stated below.
Although AMPs are promising for potential clinical use, and
their in vivo abilities to combat in vivo bacterial infections have
been demonstrated (Wilson et al., 1999; Nizet et al., 2001; Moser
et al., 2002; Yasin et al., 2004; Lopez-Leban et al., 2010) there
are some challenges that have prevented their widespread use.
First, mammalian peptides, such as the human cathelicidin LL-
37, are commonly sensitive to high salt concentrations (Goldman
et al., 1997; Johansson et al., 1998). Second, the feasibility of the
use of AMPs in the presence of bacterial and host proteases is a
considerable challenge. It was found that Pseudomonas bioﬁlms
continuously exposed to ciproﬂoxacin continuously secreted pro-
teases over a period of 4 days (Braff et al., 2005b;Oldak and Trafny,
2005), thus potentially limiting the utility of AMPs. A signiﬁcant
improvementwould be to design a protease-resistant peptide, such
as D-LL-37, if the D-peptide has the same biological effect as the
L-peptide.
Thus, this study will examine the ability of a family of cathe-
licidins and related small peptides to exert anti-microbial and
anti-bioﬁlm effects against P. aeruginosa. We will also examine the
activity of both the D and L chiral enantiomers of several of the
peptides. Finally, we will examine changes in rhlA and rhlB gene
expression in the presence of D-LL-37, to determine if the chiral
enantiomer is acting through the same mechanism as L-LL-37.
MATERIALS AND METHODS
BACTERIAL STRAINS AND MEDIA
Pseudomonas aeruginosa [ATCC 19429 and ATCC 27853 (a type
strain blood isolate), American Type Culture Collection, Manas-
sas, VA, USA] were grown in Nutrient Broth (Difco Laboratories,
Detroit, MI, USA) at 37˚C, 24 h with shaking at 200 rpm. The
CFU/ml was determined by dilution plating on Nutrient Agar
plates. For the anti-microbial assays, frozen enumerated aliquots
were thawed immediately before use.
ANTI-MICROBIAL ASSAYS
The anti-microbial activity of the NA-CATH and NA-
CATH:ATRA1-ATRA1 (AAPPTEC, Louisville, KY, USA), the
variations on theATRA peptides (Genscript, Piscataway,NJ,USA),
LL-37 (AnaSpec 61302), and D-LL-37 (Lifetein, South Plainﬁeld,
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NJ, USA) against P. aeruginosa (ATCC 19429) were determined as
previously described, with some modiﬁcation (Han et al., 2008;
Papanastasiou et al., 2009). The sequences and net charges of the
peptides are shown in Table 1.
In a 96-well plate, 1× 105 CFU per well of bacteria were incu-
bated with different peptide concentrations (in serial dilutions of
1:10 or 1:5 per dilution) in a solution of buffer containing 10mM
sodium phosphate at pH 7.4 (3 h, 37˚C). Serial dilutions were
then carried out in 1× Dulbecco’s PBS and plated in triplicate on
Nutrient Agar plates, incubated (37˚C, 24 h) and CFUs counted.
Bacterial survival at each peptide concentration was calculated as
previously described (Amer et al., 2010; de Latour et al., 2010)
based on the percentage of colonies in each experimental plate rel-
ative to the average number of colonies observed for assay cultures
lacking peptide. The peptide concentration required to kill 50% of
the P. aeruginosa in the anti-microbial assay cultures (EC50) was
determined by plotting percent survival as a function of the log of
peptide concentration (log10) and ﬁtting the data using GraphPad
Prism 5 (GraphPad Software Inc., San Diego, CA, USA), using the
equation:
Y = Bottom + (Top − Bottom)/(1 + 10[(logEC50−X)×Hill slope)])
where Y corresponds to bacterial survival (in percentage) at a
given peptide concentration (μg/ml), with X being the logarithm
of that concentration. In the equation, “Top” and “Bottom” refers
to the upper and lower boundaries, and were constrained to values
<100% and >0%, respectively. For graphing purposes, samples
that had no peptide were plotted at 10−9 μg/ml peptide. EC50
values were determined by ﬁtting the data from the anti-microbial
assays to a standard sigmoidal dose–response curve. In Figure 1,
only the range from−2.5 to 2.5 on the x-axis is shown. Each exper-
iment was repeated at least twice, and a representative experiment
is shown, for clarity. 95% conﬁdence intervals (CI) are reported to
indicate the error of each EC50 determination.
In order to study the in vitro killing kinetics of the LL-37,
D-LL-37, and NA-CATH:ATRA1-ATRA1 peptides, cultures of P.
aeruginosa (ATCC 19429) were incubated with the peptides in
10mM sodium phosphate. The concentrations used in the assay
were: 1.0μg/ml of LL-37, 1.0μg/ml of NA-CATH, and 0.73μg/ml
of NA-CATH:ATRA1-ATRA1. The anti-microbial activity of the
peptides was determined over a period of 3 h, and plated in
triplicate, as previously described (Amer et al., 2010).
CD SPECTROSCOPY
Circular dichroism (CD) spectra of the peptides were collected
using Jasco J-815 spectropolarimeter. Samples were allowed to
equilibrate for 10min at 25˚C prior to data collection in a 0.1-cm
path length cuvette, with a chamber temperature 25˚C throughout
each scan. Spectrawere collected from190 to 260 nmusing 0.2-nm
intervals; three scans per sample were averaged. All peptides were
analyzed at 250μg/ml in 10mM sodium phosphate (pH 7), 50%
(v/v) triﬂuoroethanol (TFE) in 10mM sodium phosphate (pH 7;
Lee et al., 2003).
BIOFILM PRODUCTION
Bioﬁlm production was measured as previously described
(Durham-Colleran et al.) with the following modiﬁcations.
P. aeruginosa (ATCC 19429; 1× 105 CFU) in 200μl of Trypticase
Soy Broth was incubated with peptide at concentrations of 1.0,
0.1, and 0.01μg/ml for 24 h, 37˚C. Optical density of the cultures
(OD600 nm) at 24 h was determined prior to staining as a measure
of bacterial growth. Six wells were used for each peptide concen-
tration (n = 6). Bioﬁlmproductionwasmeasured using the crystal
violet stain technique (Durham-Colleran et al.).
BIOFILM ATTACHMENT ASSAY
The bioﬁlm attachment assay was performed using an overnight
culture (OD600 = 1.0) P. aeruginosa (ATCC 19429 and ATCC
27853) in 200μl of TSB was incubated with either D- or L-LL-
37 at 1μg/ml for 1 h, 37˚C. The optical density of the cultures
(570 nm) at 1 h was determined prior to staining as a measure
of bacterial growth. Twelve wells were used for each peptide con-
centration (n = 12). Bioﬁlm production was measured using the
crystal violet stain technique (Durham-Colleran et al.).
PRE-FORMED BIOFILM ASSAY
The pre-formed bioﬁlm assay was performed using P. aeruginosa
(ATCC19429 andATCC27853; 1× 105 CFU) in 200μl of TSBwas
incubated for 24 h,37˚C. Following the formationof an established
bioﬁlm at 24 h, the bioﬁlm was treated with either D- or L-LL-37
at 1μg/ml and incubated for 24 h, 37˚C. The optical density of
the cultures (570 nm) at 48 h was determined prior to staining
as a measure of bacterial growth. Twelve wells were used for each
peptide concentration (n = 12). Bioﬁlmproductionwasmeasured
using the crystal violet stain technique (Durham-Colleran et al.).
Table 1 | Peptides used in this study.
Anti-microbial peptide Sequence Net charge
NA-CATH KRFKKFFKKLKNSVKKRAKKFFKKPKVIGVTFPF 15
NA-CATH:ATRA1-ATRA1 KRFKKFFKKLKNSVKKRFKKFFKKLKVIGVTFPF 15
ATRA-1 KRFKKFFKKLK-NH2 8
ATRA-2 KRAKKFFKKPK-NH2 8
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 6
D-LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 6
mCRAMP GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ 6
Scrambled LL-37 GLKLRFEFSKIKGEFLKTPEVRFRDIKLKDNRISVQR 6
This table indicates the sequence and charges of the anti-microbial peptides used. The ATRA motif is indicated in BOLD.
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FIGURE 1 | Effectiveness of anti-microbial peptides against
P. aeruginosa. Percent (%) survival was calculated by counting CFUs,
after 3 h incubations with various peptide concentrations in 10mM
sodium phosphate (pH 7.4). (A)The EC50s were found to be 0.52μg/ml
for NA-CATH and 0.74μg/ml for LL-37. (B) EC50s were found to be
0.37μg/ml for NA-CATH:ATRA1-ATRA1 and 0.52μg/ml for NA-CATH.
(C) EC50s were found to be 0.37μg/ml for NA-CATH:ATRA1-ATRA1
and 0.47μg/ml for LL-37. (D) EC50s were found to be 0.64μg/ml for
ATRA-1 and 62.8μg/ml for ATRA-2. (E) EC50s were found to be
0.72μg/ml for D-LL-37 and 0.47μg/ml for LL-37. (F)The peptides were
incubated in 10mM sodium phosphate with P. aeruginosa at the EC50
(0.47μg/ml for LL-37, 0.72μg/ml for D-LL-37 and 0.37μg/ml for
NA-CATH:ATRA1-ATRA1). Killing kinetics assays were plated in triplicate time
points over 3 h.
MOTILITY ASSAYS
Twitching motility of P. aeruginosa (ATCC 19429) was measured
after 16, 20, 24, and 48 h of incubation at 37˚C on LB plates con-
taining 1% (wt/vol) agar and LB broth (Overhage et al., 2008).
P. aeruginosa cells were spot inoculated using a needle, and zone
diameterswere determinedbymeasuring at least three times across
the zone. Assays were carried out with 4μg/ml of either D-LL-37
or L-LL-37, and controls. (n = 30).
EXAMINATION OF D- AND L-LL-37 SENSITIVITY TO TRYPSIN
The proteolytic stability of the enantiomers, L- and D-LL-37, was
assessed in the presence of trypsin. The peptides (18μg) were
dissolved in 90μl of water. Then, either water or 0.05% trypsin
(10μl) was added to the peptide solutions, and incubated at 37˚C
for 1 h. After incubation, 10μl aliquots were taken into an 18%
Tris-Glycine gel. After running the gel, the gel was transferred to a
clean tray and a silver stain was performed.
GALLERIA MELLONELLA EXPERIMENT
The Galleria mellonella (wax moth caterpillars) were obtained
from Vanderhorst Wholesale (Saint Marys, OH, USA). Eight to
twelve caterpillars of equal size/weight were randomly assigned to
each group. A 1-ml tuberculin syringe was used to inject 10μl
of 1× 103 CFU/ml of P. aeruginosa into each caterpillar’s central
cavity (hemocoel). The caterpillarswere then immediately injected
with 10μl of either PBS, 5μg of ciproﬂoxacin, 10μg D- or L-LL-
37, or 10μg of NA-CATH:ATRA1-ATRA1 in the dorsal side of the
caterpillar. Caterpillar control groups included: injected with only
PBS, ciproﬂoxacin, or AMPs. The insects were then observed daily
for their survival status.
ANALYSIS OF rhlA AND rhlB GENE EXPRESSION IN THE PRESENCE OF
D- AND L-LL-37 BY qRT-PCR
Quantitative real time RT-PCR analysis was performed in a MyiQ
Single Color Real-Time PCR Detection System (BioRad Laborato-
ries). 1× 103 CFUs of P. aeruginosa (ATCC 19429) were incubated
in 2ml of TSB at 37˚C for 24 h. In duplicate, from two independent
experiments, RNA from bioﬁlm formed in an untreated control,
D-LL-37 (1μg/ml) and LL-37 (1μg/ml) was isolated (RNAeasy
Mini Kit, Qiagen) and reverse transcribed (Super Script™ III
Reverse Transcriptase, Invitrogen). The protocol was performed
as previously described (Amer et al., 2010).
The primer sequence for rhlA 5′-TCTGTTGGTATCGGTTTG
CAAGGG-3′ forward and5′-ACAGCACCACGTTGAAATGTTCG
G-3′ reverse; the primer sequence for rhlB 5′-CATCGCTCACGAG
AAGTACG-3′, forward and5′-GTTGAACTTGGGGTGTACCG-3′
were obtained from Invitrogen. The relative levels of transcription
was normalized by correcting for rpoD transcription levels.
STATISTICAL ANALYSIS
Anti-microbial assay measurements were performed in triplicates,
bioﬁlm assays done at least in duplicate with n = 6 each time, and
representative experiments are shown. Standard deviations of the
mean of each set are represented on each graph. Where the error
bars cannot be seen, the error is very small. CI (95%) is presented
for EC50 determinations demonstrating the statistical overlap of
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the data. Statistically signiﬁcant differences were assessing using
Student’s t tests.
RESULTS
ANTI-MICROBIAL PERFORMANCE
Effect of chirality: D- vs L-LL-37 against P. aeruginosa
A common concern against the use of AMPs as potential therapeu-
tics is their potential sensitivity to host or bacterial proteases (Braff
et al., 2005b). In order to generate a protease-resistant peptide
mimetic of the human cathelicidin (Wade et al., 1990), we syn-
thesized an all-D-amino acid version of LL-37. The anti-microbial
EC50 for D-LL-37 against P. aeruginosa (ATCC 19429) was deter-
mined to be 0.72μg/ml, compared to 0.47μg/ml for wild-type
LL-37 (Table 2; Figure 1E); there is not a signiﬁcant difference in
anti-microbial activity between them by examining the 95% CIs.
Additionally, D- and L-LL-37 display similar killing kinetics over
the 3h duration of a killing kinetics assay against P. aeruginosa
(ATCC 19429) Figure 1F.
Small synthetic peptides demonstrate anti-microbial activity
against P. aeruginosa
Pseudomonas aeruginosa (ATCC 19429) was also subjected to
treatment with two short, synthetic peptides (Table 1), ATRA-1
and ATRA-2. These two ATRA peptides differ by two residues at
the 3rd (F/A) and 10th (L/P) position. This has been shown to
affect the anti-microbial activity of those peptides against Fran-
cisella novicida, Escherichia coli (Amer et al., 2010),Aggregatibacter
actinomycetemcomitans (de Latour et al., 2010), and Staphylococ-
cus aureus (Dean et al., 2011). The EC50 values of ATRA-1 and
ATRA-2 were determined to be statistically different (p < 0.05,
Student’s t test) at 0.64 and 62.8μg/ml, respectively (Table 2;
Figure 1D). These two peptides have the same net charge of +8,
highly similar sequence and both are 11 amino acid residues in
length.
LL-37 and NA-CATH-derived peptide are anti-microbial against
P. aeruginosa
The anti-microbial effectiveness of NA-CATH was tested against
P. aeruginosa (ATCC 19429), and the performance of this peptide
was compared to that of the well-studied cathelicidin LL-37. The
EC50 for NA-CATH was found to be 0.52μg/ml (Figure 1A). The
peptide NA-CATH:ATRA1-ATRA1 incorporates modiﬁcations to
the NA-CATH sequence in which the secondATRA motif has been
changed to match the sequence of the ﬁrst ATRA motif (Table 2)
thus creating a perfect repeat. This synthetic cathelicidin had an
EC50 value that was determined to be 0.37μg/ml, not statisti-
cally more effective against P. aeruginosa (ATCC 19429) than the
NA-CATH parent peptide (Figure 1B), or LL-37 (Figure 1C). We
previously demonstrated that the alterations made to NA-CATH
to create NA-CATH:ATRA1-ATRA1 resulted in a statistically sig-
niﬁcant (p < 0.05, Student’s t test) improvement in anti-microbial
activity against S. aureus (Dean et al., 2011).
In agreement with reported potencies (Gordon et al., 2005),
we found that the EC50 for LL-37 is 0.47μg/ml. This is within the
range of the level of LL-37 reported in human plasma (1.18μg/ml;
Sorensen et al., 1997), suggesting that this is a physiologically
relevant potency of LL-37.
INHIBITION OF ATTACHMENT AND BIOFILM FORMATION, AND
DEGRADATION OF ESTABLISHED P. AERUGINOSA BIOFILM AT
SUB-ANTI-MICROBIAL CONCENTRATIONS
A concern of the utility of AMPs as potential therapeutics is the
sensitivity of the anti-microbial activity to salt. Multiple studies
have shown that LL-37 demonstrates reduced anti-microbial
action in environments with high ionic concentrations (Travis
et al., 2000; Cox et al., 2003) such as in physiologic salt con-
centration (123–150mM NaCl). However, LL-37 can inhibit
bioﬁlm formation by P. aeruginosa PAO1 (Overhage et al., 2008),
S. epidermidis (Hell et al., 2010), F. novicida (Amer et al., 2010),
and S. aureus in media with high concentrations of salt. LL-37
is reported to be capable of degrading pre-formed bioﬁlms of
S. aureus and P. aeruginosa (Altman et al., 2006; Overhage et al.,
2008).
In this study, we demonstrate similar salt-independent anti-
bioﬁlm activity for D-LL-37 against P. aeruginosa. We incubated
various concentrations of NA-CATH, NA-CATH:ATRA1-ATRA1,
LL-37, D-LL-37, mCRAMP, and scrambled LL-37 with P. aerug-
inosa in bioﬁlm experiments in TSB (relatively high salt; 86mM
NaCl) for 24 h. Both mCRAMP, a murine-homolog of LL-37 (67%
identical to LL-37 in amino acid sequence), and scrambled LL-37
(identical amino acids in random order) functioned as negative
controls for this experiment; the former was previously known
to have no inhibitory effect (Overhage et al., 2008). The scram-
bled version of LL-37, having the same charge and net amino acid
composition as LL-37, but lacking signiﬁcant helical character,
showed no inhibition of bioﬁlm formation at any concentration
Table 2 | EC50s of AMPs against P. aeruginosa.
Anti-microbial peptide Molecular weight (g/mol) EC50 (μg/ml) 95% CI EC50 (μM)
NA-CATH 5885.5 0.52 0.39–0.69 0.09
NA-CATH:ATRA1-ATRA1 5977.6 0.37 0.21–0.63 0.06
ATRA-1 2409.06 0.64 0.52–0.79 0.27
ATRA-2 2316.96 62.8 27.7–949 27.1
LL-37 5177.42 0.47 0.28–0.78 0.09
D-LL-37 5177.42 0.72 0.37–1.36 0.14
This table indicates the EC50 of the peptides against P. aeruginosa in an anti-microbial assay. The molecular weight reported here for each peptide reﬂects the TFA
salts of the peptides. These molecular weights were then used to convert the EC50 in μg/ml to μM, to enable comparisons on a molecule-by-molecule basis.
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tested (Figure 2B), thus demonstrating sequence speciﬁcity of the
anti-bioﬁlm effect.
Figures 2A–C shows that levels of bacterial growth (OD600 nm
at 24 h) were not decreased even at the peptide concentrations
equal to that of its calculated EC50 in 10mM sodium phosphate.
We could not calculate the MIC because there was no inhibi-
tion of growth at any concentration tested, thus MIC > 1μg/ml.
When the bioﬁlm production was determined in the presence of
varying amounts of peptide, there was signiﬁcant inhibition of
bioﬁlm formation by L- and D-LL-37; all other peptides were
FIGURE 2 | D- and L-LL-37 inhibit biofilm formation and attachment,
stimulate twitching motility, and degrade biofilm of P. aeruginosa. (A–C)
Inhibition of P. aeruginosa bioﬁlm formation was demonstrated for D- and
L-LL-37 (A,C), while scrambled LL-37, NA-CATH, NA-CATH:ATRA1-ATRA1
(indicated by A1-A1) and mCRAMP all showed a lack of anti-bioﬁlm activity
(B). Growth (absorbance at 600 nm) is indicated by light gray bars with “0
peptide” control set to 100%. Bioﬁlm detection on a polystyrene 96-well plate
at 37˚C after 24 h of growth in TSB was detected as the absorbance of crystal
violet stain (570 nm). Percent bioﬁlm production is indicated by dark gray bars
(n= 6), relative to “0 peptide” control. Each experiment is a representative of
at least two independent trials. Error bars indicate the standard deviation from
the mean. The asterisk (*) indicates statistically different than the positive
control (p < 0.01). (D) D- and L-LL-37 increased the rate of twitching motility in
P. aeruginosa. Motility was measured after 16, 20, and 24 h of incubation at
37˚C on plates containing 1% (wt/vol) agar and LB broth. Plates were
inoculated using a needle, and diameters were recorded. Assays were carried
out with 4μg/ml of either D-LL-37 or L-LL-37, and controls. (n= 30). (E)
Attachment assays were performed in the presence of 1μg/ml of D- or
L-LL-37; ATCC 19429 is indicated by white columns, ATCC 27853 is
represented by black columns. (F) Pre-formed bioﬁlm assays were performed
in the presence of 1μg/ml D- or L-LL-37; ATCC 19429 is indicated by white
columns, ATCC 27853 is represented by black columns.
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ineffective. Thus, LL-37 was found to inhibit bioﬁlm forma-
tion up to ∼50% of control at 1μg/ml (Figure 2C). D-LL-37
was also found to be an active anti-bioﬁlm peptide, with maxi-
mal bioﬁlm inhibition observed at 1μg/ml, inhibiting ∼50% of
bioﬁlm formation (Figure 2B).
In addition to showing that D- and L-LL-37 can inhibit the for-
mation of P. aeruginosa (ATCC19429),we determined thatD- and
L-LL-37 signiﬁcantly reduces attachment at 1μg/ml (Figure 2E)
after 1 h for P. aeruginosa (ATCC 19429 and ATCC 27853). Sug-
gesting a possible mechanism for bioﬁlm inhibition. The amount
of inhibition of attachment (∼15–22% for LL-37, and ∼39% for
D-LL-37) may not account for the full ability of the peptides
to inhibit bioﬁlm formation at the same concentration, but may
contribute to this effect.
In order to determine the ability of D- and L-LL-37 to degrade
pre-formed bioﬁlm of P. aeruginosa (ATCC 19429 and ATCC
27853), the bacteria were allowed to establish bioﬁlm for 24 h,
then the wells were treated with either D- or L-LL-37 (1μg/ml).
After incubation with peptide, bioﬁlm production was quantiﬁed
with the crystal violet stain method (Durham-Colleran et al.), and
signiﬁcant degradation of established P. aeruginosa bioﬁlm was
observed (Figure 2F).
D- AND L-LL-37 STIMULATES TWITCHING MOTILITY
Twitching motility is required for the formation of Pseudomonas
bioﬁlm (O’Toole and Kolter, 1998). To assess the ability of D-LL-
37 and L-LL-37 to stimulate twitching motility of P. aeruginosa
(ATCC 19429), we tested the bacteria in the presence of these
peptides. Both D- and L-LL-37 stimulated the rate of twitching
motility (Figure 2D) at low concentrations of peptide (4μg/ml).
This signiﬁcant (p < 0.01, Student’s t test) increase in the rate of
twitching on surface motility was 1.7 and 1.9mm/h on LB (1%
agarose) plates, for D- and L-LL-37, respectively. P. aeruginosa in
the absence of peptide,was determined to have a twitchingmotility
rate of 0.7mm/h. LL-37 has been shown to have an insigniﬁcant
effect on the swimming and swarming motility of P. aeruginosa
PAO1 (Overhage et al., 2008); neither D- nor L-LL-37 appeared to
effect swimming and swarming motility of P. aeruginosa (ATCC
19429) in this study (data not shown).
RHAMNOSYLTRANSFERASES ARE DOWNREGULATED IN THE
PRESENCE OF D- AND L-LL-37
qRT-PCR was used to determine the total amount of rhlA and rhlB
mRNA following treatment by of 1μg/ml of either D- or L-LL-37.
We determined that both peptides signiﬁcantly downregulated the
expression of these genes involved in the Rhl quorum sensing sys-
tem in P. aeruginosa (ATCC 19429; Table 3). D-LL-37 had a −7.2
and −3.0 fold change in regulation of rhlA and rhlB, respectively,
relative to the control.
CD SPECTRAL ANALYSIS OF THE SECONDARY STRUCTURE OF D- AND
L-LL-37
Circular dichroism spectra of the peptides were obtained for D-
and L-LL-37. Pronounced dichroic minima at 222 and 208 nm
are traits of helical peptides. Cathelcidins often exhibit little heli-
cal behavior at low concentrations in aqueous buffer (Johansson
et al., 1998), assuming their most helical structure when in asso-
ciation with a biological membrane or a hydrophobic membrane
mimic such as TFE, a strongly helix-promoting environment. The
stable helical characterwhen interactingwith bacterialmembranes
may contribute to their potent anti-microbial activity (Park et al.,
2004).
The spectra for L- and D-LL-37 in 10mM sodium phosphate
(pH 7.4) exhibit helical character, which is consistent with the
results reported by Johansson et al. (1998). As was expected,
the spectrum for D-LL-37 is the mirror image of that of the
L-enantiomer (Figure 3A). Under these conditions, the conforma-
tion of L-LL-37 is estimated to have ∼28% alpha-helical content
and that of D-LL-37 has ∼19% helical content. The spectra for
both D- and L-LL-37 in 50% TFE (a membrane mimic) in 10mM
sodiumphosphate (pH7.4) show signiﬁcantly greater helical char-
acter,∼48% and ∼58%, respectively. The helical content of these
peptides was estimated based on their respective ellipticities at
208 nm using the method reported by Greenﬁeld and Fasman
(1969).
D-LL-37 IS RESISTANT TO TRYPSIN
Figure 3B shows the stability of the enantiomeric pair of peptides,
D- and L-LL-37, in the presence of 0.05% trypsin, after incuba-
tion for 1 h at 37˚C. The L-form peptide, LL-37 at 200μg/ml, was
100% digested by the protease after the 1-h incubation. D-LL-37
at 200μg/ml showed no degradation in presence of trypsin with
equal band intensities as quantiﬁed by densitometry (NIH ImageJ,
data not shown).
GALLERIA MELLONELLA INFECTION BY P. AERUGINOSA WITH AMP
AND ANTIBIOTIC TREATMENTS
The wax moth caterpillar Galleria mellonella infected with
P. aeruginosa was used as a model in vivo system (Jander et al.,
2000) to study the effectiveness of treatment with selected AMPs.
Table 3 | Pseudomonas aeruginosa genes downregulated in the presence of D- or L-LL-37.
Treatment Identification Protein Designation Fold change p-value
L-LL-37 (1μg/ml) PA3478 Rhamnosyltransferase chain B rhIB −8.4 2.73E-02
L-LL-37 (1μg/ml) PA3479 Rhamnosyltransferase chain A rhIA −4.5 6.36E-03
D-LL-37 (1μg/ml) PA3478 Rhamnosyltransferase chain B rhIB −7.2 6.50E-04
D-LL-37 (1μg/ml) PA3479 Rhamnosyltransferase chain A rhIA −3.0 4.11E-06
This table indicates the fold change (relative to the control) in regulation of P. aeruginosa genes rhlA and rhlB in the presence of 1μg/ml of either D- or L-LL-37 in
bioﬁlm. The relative levels of transcription was normalized by correcting for rpoD transcription levels.
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FIGURE 3 | Chirality affects D-LL-37 susceptibility to proteases. (A)The
spectra for L- and D-LL-37 (125μM) exhibit signiﬁcant helical character in
pH= 7.4 10mM sodium phosphate. As expected, the spectrum for D-LL-37
(•) is the mirror image of that of the L-peptide (◦). The spectra for both D-
and L-LL-37 (≤ and, ′ respectively) become more intense when the peptides
are in 50%TFE in pH 7.4 10mM phosphate, consistent with the peptides
exhibiting more helical character. These results are consistent with what has
been reported in the literature for these peptides. (B) D-LL-37 demonstrated
resistance degradation by trypsin. Peptides (18μg) were dissolved in water
(90μg) with either water or 0.05% trypsin (10μl) and incubated (37˚C, 1 h).
10μl aliquots were then taken, and a silver stain was performed. Lane 1,
LL-37; Lane 2, LL-37 with trypsin; Lane 3, D-LL-37; Lane 4, D-LL-37 with trypsin.
G. mellonella were infected with either 1× 103 CFU bacteria of
P. aeruginosa (ATCC 19429) and immediately treated with a single
dosing of 10μl PBS (no treatment control), 5μg ciproﬂoxacin,
10μg LL-37, 10μg D-LL-37, or 10μg NA-CATH:ATRA1-ATRA1
(data not shown; Figure 4). Multiple controls were utilized (PBS,
and injections of non-infected G. mellonella with the treatment
FIGURE 4 |Treatment of P. aeruginosa-infected G. mellonella. D- and
L-LL-37 significantly prolonged the survival of G. mellonella infected
with 1× 103 CFU P. aeruginosa. Non-infected control groups consisted of
a PBS injection, 5μg Ciproﬂoxacin injection, 10μg LL-37 injection, or a
10μg D-LL-37 injection. All non-infected groups fair similarly to the PBS only
group (data not shown). The non-infected PBS only group experienced the
highest survival rate and was signiﬁcantly different from all other groups
(p-value< 0.002). The infected group without treatment failed to survive
beyond 24 h. A single dose of 5μg ciproﬂoxacin, or 10μg of either D- or
L-LL-37 was found effective when compared to the infected control group
(p-value< 0.01), but not different from each other overall. At 48 h D-LL-37
was found to be more effective than L-LL-37 (p-value< 0.04)
NA-CATH:ATRA1-ATRA1 (10 (μg), also tested, was determined to be
ineffective at prolonging survival, as this group failed to survive past 24 h
(data not shown).
used in the experiment) in order to measure the effects that the
injection or the anti-microbials have on the host system. These
negative controls had similar effects; no death was observed (data
not shown). In the positive contol, no P. aeruginosa-infected
G. mellonella survived beyond 24 h. The ciproﬂoxacin (60%) and
D-LL-37 (60%) treated groups demonstrated similarly prolonged
survival (p-value< 0.01) and were not statistically different from
each other overall. D-LL-37 was shown to be signiﬁcantly more
effective than LL-37 (p-value< 0.01) over the duration the exper-
iment. NA-CATH:ATRA1-ATRA1 treatment did not improve
survival, with all G. mellonella dead by 24 h (not shown). There
was no signiﬁcant difference in the survival rate between D- and
L-LL-37.
DISCUSSION
In this study, we present novel peptides that address some of
the challenges that have prevented the widespread use of AMPs.
Among these concerns are the noted sensitivity of their anti-
microbial activity to high salt concentrations (Goldman et al.,
1997; Johansson et al., 1998) and the sensitivity of AMPs to bacter-
ial andhost secretions of proteases (Braff et al.,2005b).Wedescribe
the anti-microbial and anti-bioﬁlm activity of these peptides.
We were able to demonstrate that LL-37 and its D-enantiomer,
D-LL-37,NA-CATH, and NA-CATH-derived peptides have strong
anti-microbial activity against the Gram-negative opportunistic
pathogen, Pseudomonas aeruginosa. The effective peptides’ EC50
values,when converted fromμg/ml toμMto reﬂect the number of
molecules of peptide and to accommodate the different molecular
weights of the peptides, ranged from 0.06 to 0.27μM. The lowest
EC50 belonged to NA-CATH:ATRA1-ATRA1, consistent with our
prior observations for other bacteria (Dean et al., 2011).
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Based on earlier work (Amer et al., 2010; de Latour et al., 2010),
we determined that when using SDS is as amodel system for study-
ing the structural properties of AMPs and their interaction with
negatively chargedmembranes (Tack et al., 2002;Wang,2008), that
the degree of helical propensity had a signiﬁcant correlation with
anti-microbial activity. However, NA-CATH:ATRA1-ATRA1 and
NA-CATH were ineffective in inhibiting bioﬁlm formation despite
being highly effective AMPs, and highly helical.
We were able to determine that both L- and D-LL-37 were
able to inhibit the development of bioﬁlms in two ways: through
stimulatory activity in twitching motility assays, as well as anti-
bioﬁlm activity in anti-bioﬁlm assays. In conﬁrmation with a
previous study (Overhage et al., 2008), we demonstrated that
LL-37 promotes twitching in P. aeruginosa. Twitching is a form
of surface motility that is regulated by type IV pili (Whitchurch
et al., 1991). LL-37 accomplished this increase in twitching by
up-regulating genes related to this form of motility (Overhage
et al., 2008), which in turn causes the bacteria to move instead
of forming bioﬁlm. This action has been shown to signiﬁcantly
lower the net mass of P. aeruginosa bioﬁlm (Singh et al., 2002;
Picioreanu et al., 2007). We have also demonstrated the equiv-
alently stimulatory activity of D-LL-37 at increasing the rate of
Pseudomonas surface motility. Thus, we believe that the abil-
ity of the peptides to stimulate twitching motility and thus
inhibit bioﬁlm formation in Pseudomonas is independent of
peptide chirality.
Considering that the formation of bioﬁlm protects bacteria
during infections, such as in chronic wound and hospital-related
pneumonia (Costerton et al., 1999; Prince, 2002; Dieter, 2004;
Kaneko et al., 2007), the inhibition of bioﬁlm formation by
these AMPs is a critically important quality as a potential ther-
apeutic, possibly more so than their anti-microbial activity. In
our anti-bioﬁlm assays, we were able to demonstrate that both
L-LL-37 and D-LL-37 are capable of inhibiting P. aeruginosa
bioﬁlm formation to similar extents (∼50%, Figures 2A,C), this
result compares well to other studies (Overhage et al., 2008).
In addition, D-LL-37 downregulated rhlA and rhlB gene expres-
sion to a similar extent as reported for L-LL-37 (Overhage et al.,
2008), suggesting that they may share a conserved mechanism
of action.
We have previously shown that LL-37, D-LL-37, NA-
CATH:ATRA1-ATRA1, NA-CATH, and ATRA at concentration of
100μg/ml elicited no signiﬁcant hemolysis against red blood cells
(de Latour et al., 2010; Dean et al., 2011), suggesting that these
peptides have very low host-cell cytotoxic effects (Ryadnov et al.,
2002).
To address the effectiveness of AMPs to thwart in vivo infec-
tion, we studied the abilities of select peptides in comparison to
treatment with an established antibiotic in the wax moth cater-
pillar model system Galleria mellonella. G. mellonella has been
shown to be a good model for the determination of the effects
of virulence during infection by P. aeruginosa when compared
to the mouse model (Jander et al., 2000). In this experiment, we
determined thatPseudomonas-infectedG.mellonella,when treated
with ciproﬂoxacin,L-LL-37, andD-LL-37,have a signiﬁcantly pro-
longed survival time when compared to the no-treatment control
group. Further, D-LL-37 displays signiﬁcant effectiveness when
compared to the L-LL-37 and ciproﬂoxacin-treatment groups at
48 h (Figure 4). One interesting result is in the NA-CATH:ATRA1-
ATRA1-treatment group, when all of the caterpillars were dead at
24 h, despite the peptide exhibiting strong in vitro anti-microbial
activity. While NA-CATH:ATRA1-ATRA1 was determined to be
the most effective AMP in our sodium phosphate study, it did
not display anti-bioﬁlm activity against P. aeruginosa. From this
result, we suggest that the inability of NA-CATH:ATRA1-ATRA1
to prolong survival of G. mellonella could be attributed to the lack
of anti-bioﬁlm activity, thus exemplifying the importance of this
anti-bioﬁlm property for the potential AMP’s future therapeutic
applications.
Finally, we addressed the sensitivity of AMPs to proteolytic
degradation. It has been shown for mammalian hosts and sev-
eral bacteria, including P. aeruginosa and S. aureus, that they
express proteases capable of degrading and inactivating LL-37
(Sieprawska-Lupa et al., 2004). In addition, other peptides that are
capable of preventing the formation of bioﬁlm, such as lactoferrin
(Singh et al., 2002), are also degraded and inactivated in the
presence of bacterial and host proteases. In our study, we have
determined that the protease trypsin does not degrade D-LL-37
(Figure 3) while L-LL-37 is completely degraded and therefore
experiences a loss of function. Protease resistance and the CD
spectra are the two main aspects in which the chirality of the pep-
tide appears to be critical. In all other aspects measured in this
study, they are equivalent. This property of protease resistance
may allow D-LL-37 peptide to remain active when applied to a
wound despite protease production and therefore may be able to
inhibit bioﬁlm formation in vivo. We will test this hypothesis in
future studies.
Novel treatments for chronic wounds, pneumonia, and med-
ical implant-associated infections are critically needed. These
infections are often characterized by polymicrobial infections by
bioﬁlm-forming bacteria, including P. aeruginosa (James et al.,
2008,Murray, 2008). Desired characteristics of a novel therapeutic
for these wounds would include a broad-spectrum, anti-bioﬁlm
treatment that is capable of withstanding the host environment,
including protease secretions. We previously demonstrated the
effectiveness of D-LL-37 to inhibit bioﬁlm formation of S. aureus,
another pathogen commonly found in infected wounds (Dean
et al., 2011). In this work, we explore the ability of an enantiomer
of a naturally occurring AMP to inhibit bioﬁlm formation and
treat infection by P. aeruginosa. D-LL-37 represents a potential
therapeutic candidate by being a protease-resistant peptide that
is effective in inhibiting bioﬁlm formation, increasing the rate of
twitching motility, and possesses potentially wound-healing prop-
erties toward the host (Picioreanu et al., 2007), while increasing
the survival time of infected wax-moth caterpillars. For exam-
ple, such a peptide may have potential to be developed as topical
treatments for bioﬁlm-forming bacteria in skin wounds, such as P.
aeruginosa. It may be more appropriate to refer to these peptides
as anti-bioﬁlm peptides rather than AMPs, reﬂecting the current
understanding of the role of bioﬁlms in infection. Incorporation
of anti-bioﬁlm peptides or their synthetic derivatives in thera-
peutic topical applications may improve outcomes for infections
ranging from chronic wounds, burns, implanted medical devices
and pneumonia.
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